Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Travere Therapeutics (TVTX) Long-Term Investments (2018 - 2019)

Travere Therapeutics' Long-Term Investments history spans 3 years, with the latest figure at $15.0 million for Q2 2019.

For Q2 2019, Long-Term Investments changed 0.0% year-over-year to $15.0 million; the TTM value through Jun 2019 reached $15.0 million, changed 0.0%, while the annual FY2018 figure was $15.0 million, N/A changed from the prior year.
Long-Term Investments reached $15.0 million in Q2 2019 per TVTX's latest filing, roughly flat from $15.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $15.0 million in Q1 2018 to a low of $15.0 million in Q1 2018.